CUTANEOUS MANIFESTATION DURING ANTI-TNF THERAPY IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
Anti-TNF antibodies play an important role in the management of IBD, rheumatologic diseases, psoriasis. They have a good safety profile but many studies have reported some adverse reactions. Skin manifestations are the most common adverse events and occur in 20¿25% of patients (pts). There are only few data on cutaneous manifestations during anti-TNF¿ therapy in IBD children.
The purpose of our study is to describe cutaneous adverse events in a cohort of pediatric pts receiving biological therapy for IBD. We conduct an observational study among IBD patients follow at our Unit receiving anti-TNF¿ therapy (Infliximab, IFX or Adalimumab, ADA).Therapy duration, time of onset, type(s) and location of skin manifestation, concomitant use of immunomodulators (IM) and corticosteroids(CS), severe systemic events will report. Pts with skin manifestations will refer to a dermatologist for a more accurate diagnosis.